Abstract 3400
Background
Dermatologic toxicities related to radiotherapy treatments affect substantially the patient’s quality of life. It is well stated that the causes are closely related to the radiotherapy treatment technique and to the individual genetic variation factors. More specifically, the received by each skin point is suggested as one of the most important among those causes. But there are still no studies proving this correlation as the skin radiation dose is only assessed within a 15% uncertainty using the current feasible procedures in a common department. On the contrary, we would expect a good correlation, even more, stating a skin-toxicities predicting method by assessing the skin dose using a feasible 5% uncertainty procedure.
Methods
Prospective transversal study of breast cancer patients receiving normofractionated external radiation therapy, without bolus compensator. This study uses a non-invasive innovative method to obtain accurate skin radiation doses based in a Software as a Service and radiochromic films.The prescribed dose, the dose report from the Treatment Planning System as well as its class and version, the irradiated volume and measured skin dose and extension by means of this innovative method at fractions 1, 2, 3, 15, 25 and end of treatment will be collected and correlated to acute skin toxicities of the patients. This will be performed using the Radiation Therapy Group gradation during the nurse visit ongoing- and post-treatment till 90 days since its ending.
Results
This study will state a skin radiation dose – toxicity relationship for breast cancer patients as a result of a Pearson correlation coefficient analysis for each pair of variables.
Conclusions
The most common action in a nurse care plan is to treat signs and symptoms of the dermatologic toxicities but its causes are excluded, mainly due to a lack of knowledge. This study tries to formally state the skin radiation dose – toxicities relationship and, furthermore, the theoretical bases to determine and predict the skin radiation toxicities grade for each treatment. Even more, this will become a useful tool to improve the treatment success probability as well as empowering nursing for designing more accurate patient-specific radiotherapy care plans.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2262 - Real world experience of Nivolumab therapy in Metastatic Renal Cancer patients: a 3 year multi-centre review
Presenter: Joanna Hack
Session: Poster Display session 3
Resources:
Abstract
4441 - “A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC).”
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
2613 - Lenvatinib (Len) alone or in combination with Everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitors (ICI) and VEGFR-targeted therapies: A single-institution experience
Presenter: Andrew Wiele
Session: Poster Display session 3
Resources:
Abstract
3249 - Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC).
Presenter: Emeline Colomba
Session: Poster Display session 3
Resources:
Abstract
2405 - Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma.
Presenter: Felix Lefort
Session: Poster Display session 3
Resources:
Abstract
4020 - Skeletal muscle loss as an adverse event during Cabozantinib treatment in patients with metastatic renal cell carcinoma
Presenter: Carolina Alves Costa Silva
Session: Poster Display session 3
Resources:
Abstract
2407 - Long term relative survival (RS) in patients with primary metastatic kidney cancer (primary mRCC): an analysis of 2,167 patients from the Austrian National Cancer Registry (ANCR).
Presenter: Monika Hackl
Session: Poster Display session 3
Resources:
Abstract
2470 - Advanced renal cell carcinoma: first results from the prospective research platform CARAT for patients with mRCC in Germany
Presenter: Peter Goebell
Session: Poster Display session 3
Resources:
Abstract
1533 - Are immune checkpoint inhibitors a valid option for papillary Renal Cell Carcinoma? Transcriptomic characterization of the immune infiltrate
Presenter: Manon De Vries-brilland
Session: Poster Display session 3
Resources:
Abstract
3367 - Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma
Presenter: Meredith Regan
Session: Poster Display session 3
Resources:
Abstract